Skip to main content
. 2018 Oct 30;20(1):135–145. doi: 10.1007/s40257-018-0395-0

Table 3.

Patient-reported outcomes: change from baseline (ASDD items, DLQI/CDLQI) and at week 4 (HDSS Responder Rate, Weekly Impact items and PGIC)

ATMOS-1 ATMOS-2
Vehicle GT Vehicle GT
Primary efficacy PRO outcomea
 ASDD/ASDD-C Item 2 (sweating severity) responder rate (≥ 4-point improvement from baseline), % of patients 28.3 [n = 115] 52.8*** [n = 229] 26.9 [119] 66.1*** [234]
Supportive efficacy PRO outcomesb
 HDSS responder rate (≥ 2-grade improvement from baseline)a, % of patients 23.7% [n = 115] 56.5*** [n = 229] 27.8 [n = 119] 61.6*** [n = 234]
ASDD/ASDD-C Item 2 (sweating severity), mean % improvement from BL n = 115 n = 229 n = 119 n = 234
 Week 1 15.1 31.1 16.9 36.9
 Week 2 25.4 48.8 26.5 55.4
 Week 3 30.3 54.8 34.8 62.4
 Week 4 31.2 57.8 35.2 64.1
ASDD Item 3 (impact), mean % improvement from BL
 Week 1 17.3 [n = 106] 33.8 [n = 212] 20.3 [n = 102] 42.8 [n = 212]
 Week 2 30.0 [n = 102] 49.6 [n = 207] 31.1 [n = 94] 63.3 [n = 200]
 Week 3 33.8 [n = 101] 53.3 [n = 193] 41.5 [n = 99] 68.9 [n = 195]
 Week 4 38.2 [n = 98] 60.2 [n = 186] 42.6 [n = 93] 70.9 [n = 183]
ASDD Item 4 (bothersomeness), mean % improvement from BL
 Week 1 15.8 [n = 107] 36.9 [n = 215] 19.0 [n = 105] 43.6 [n = 213]
 Week 2 29.2 [n = 103] 54.3 [n = 210] 32.3 [n = 97] 63.3 [n = 201]
 Week 3 32.4 [n = 102] 60.8 [n = 196] 40.9 [n = 101] 67.6 [n = 196]
 Week 4 34.2 [n = 99] 62.7 [n = 189] 44.1 [n = 96] 68.1 [n = 184]
WI items at week 4, % of patients n = 109 n = 224 n = 109 n = 222
 Needed to change shirt during the day 50.5 32.1 55.0 22.5
 Needed ≥1 shower/bath a day 43.1 23.7 24.8 14.9
 Felt less confident 58.7 38.8 61.5 33.3
 Felt embarrassed 63.3 43.8 67.0 39.2 [n = 221]
 Avoided interactions 34.9 17.9 34.9 15.8
 Kept from doing an activity 21.1 13.8 31.2 10.8
PGIC at week 4,** % of patients n = 115 n = 229 n = 119 n = 234
 Score = 1 Much better 17.6 52.3 26.0 63.7
 Score = 2 Moderately better 20.6 21.3 14.6 16.7
 Score = 3 A little better 32.4 17.8 22.9 14.2
 Score = 4 No Difference 24.5 8.1 32.3 4.9
 Score  = 5, 6 or 7 A little to much worsec 4.9 0.5 4.2 0.5
DLQI, change from BL to week 4, mean ± SD [n] − 4.3 ± 5.9 [n = 105] − 8.1 ± 5.8*** [n = 202] − 5.0 ± 6.2 [n = 101] − 8.6 ± 6.2*** [n = 203]
CDLQI, change from BL to week 4, mean ± SD [n] − 1.6 ± 3.7 [n = 7] − 7.5 ± 6.1 [n = 8] − 2.1 ± 6.5 [n = 12] − 8.4 ± 5.2* [n = 15]

ANCOVA analysis of covariance, ASDD Axillary Sweating Daily Diary, ASDD-C children’s version of the ASDD (two items), BL baseline, CDLQI children’s Dermatology Life Quality Index, DLQI Dermatology Life Quality Index, GT topical glycopyrronium tosylate, HDSS Hyperhidrosis Disease Severity Scale, PGIC Patient Global Impression of Change, PRO patient-reported outcome, SD standard deviation, WI Weekly Impact

*p < 0.05 for GT vs. vehicle at week 4 from an ANCOVA with factors of treatment group and analysis center and a covariate of baseline score

**p < 0.01 for GT vs. vehicle for both trials from an ANCOVA with factors of treatment group and analysis center

***p < 0.001 for GT vs. vehicle at week 4. For ASDD/ASDD-C Item 2 and HDSS responder rates, the analysis was a Cochran–Mantel–Haenszel test stratified by analysis center. For DLQI/CDLQI, the analysis was an ANCOVA with factors of treatment group and analysis center and a covariate of baseline score

aPrespecified statistical comparison

bNo prespecified statistical analysis was performed for ASDD Items 3, 4, and WI items; prespecified analyses were performed for DLQI/CLQI, while a post hoc statistical comparison was performed for PGIC

cFor the PGIC, no patients in either the ATMOS-1 or ATMOS-2 trials rated their change as “moderately worse” (score = 6) or “much worse” (score = 7); therefore, these categories were combined with the category of “a little worse” (score = 5)